Trials / NCT02320812
Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa
Completed Phase 1 / Phase 2 Cell therapy
- Sponsor
- jCyte, Inc
- Treatment
- human retinal progenitor cells
- Gene
- Not gene-specific
- Conditions
- Retinitis Pigmentosa (RP)
- Ages
- 18 Years to no upper limit
- Enrollment
- 28 participants
- Started
- 2015-06
- Main results expected
- 2017-07-19
- Results posted
- Yes
- Record last updated
- 2019-03-05
What the study is testing
This study evaluates the safety and potential activity of a single dose of live human retinal progenitor cells (jCell) administered to adults with retinitis pigmentosa. Four different dose levels of cells will be assessed in each of two groups of patients.
Where it runs
United States (2)
- The Gavin Herbert Eye Institute, Univ California Irvine, Irvine, California
- Retina-Vitreous Associates Medical Group, Los Angeles, California